Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study of its investigational dual GLP-1/GIP receptor agonist, CT-388. The study is assessing the drug’s effects in obese adults, both healthy and those with type 2 diabetes (T2D). Initial data from the healthy cohort showed that a 24-dose regimen over a week led to a significant mean placebo-adjusted weight loss of 18.8%, with all participants experiencing over 5% weight loss and 45% achieving more than 20% weight reduction.
In the pre-diabetic patient group, the treatment successfully normalized glucose levels. The molecule demonstrated a favorable tolerability profile, with the most common side effects being gastrointestinal reactions typical of incretin-based drugs.
The study is on track to conclude in the second half of 2024, following a comprehensive evaluation of data from the T2D cohort.- Flcube.com
